Hepatitis C virus and death risk in hemodialysis patients

Kamyar Kalantar-Zadeh1, Ryan D Kilpatrick, Charles J McAllister

  • 1Harold Simmons Center for Kidney Disease Research and Epidemiology, Los Angeles Biomedical Institute at Harbor-UCLA Medical Center, Torrance, CA 90509-2910, USA. kamkal@ucla.edu

Insights

Hepatitis C virus (HCV) infection in maintenance hemodialysis patients is linked to increased all-cause and cardiovascular mortality. Early detection and treatment of HCV may improve survival rates in this vulnerable population.

Area of Science:

  • Nephrology
  • Infectious Diseases
  • Epidemiology

Background:

  • Hepatitis C virus (HCV) infection is prevalent in maintenance hemodialysis (MHD) patients.
  • HCV infection may negatively impact clinical outcomes in MHD patients.

Purpose of the Study:

  • To investigate the association between HCV infection and all-cause and cardiovascular mortality in MHD patients.
  • To identify demographic and clinical factors associated with HCV infection in MHD patients.

Main Methods:

  • Analysis of a national database of 13,664 MHD patients tested for HCV antibodies between July 2001 and June 2004.
  • Logistic regression and proportional-hazards regression models were used to assess associations with mortality, controlling for covariates.

Main Results:

  • HCV infection was identified in 12% of patients and associated with younger age, male gender, minority race/ethnicity, Medicaid insurance, longer dialysis vintage, and HIV infection.
  • HCV infection was independently associated with a 25% increased risk of all-cause and cardiovascular mortality (hazard ratio 1.25).
  • Higher mortality risks were observed in both incident and prevalent hemodialysis patients with HCV across various subgroups.

Conclusions:

  • HCV infection in MHD patients has distinct demographic and clinical patterns.
  • HCV infection is a significant independent risk factor for increased all-cause and cardiovascular mortality in MHD patients.
  • Enhanced prevention and treatment strategies for HCV are crucial to improve outcomes in MHD patients.

Related Concept Videos

Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Dialysis01:27

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Dialysis01:15

Dialysis

Dialysis is a diffusion-based purification process that separates analyte molecules from a complex matrix. This is accomplished by allowing molecules in the solution to pass through a semipermeable membrane into a liquid on the other side. The membrane is usually made of cellulose acetate or cellulose nitrate, and the second liquid must be miscible with the solution. Ions (e.g., chloride or sodium) or organic molecules (e.g., glucose) can pass through the membrane pores, which generally have...